Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
Date of Report: November 13, 2015 (Event Date); Filed November 16, 2015.
Company: Xenetic Biosciences, Inc. (Nevada corporation).
Event: Entry into a Material Definitive Agreement (Asset Purchase Agreement) with AS Kevelt and OJSC Pharmsynthez (collectively, "Sellers").
The Company and its subsidiary, Lipoxen Technologies, LTD, acquired worldwide rights to develop, market, and license the immunomodulator product Virexxa, excluding specific uses in Russia and the Commonwealth of Independent States. The transaction involves significant equity issuance, debt financing, and a requirement for a future capital raise.
Key Financial Metrics and Transaction Terms
This filing details a restructuring of capital and asset acquisition rather than standard operating financial results. Key financial terms include:
- New Debt Financing: Pharmsynthez will loan the Company $3.5 million in tranches (the "New Loan").
- Debt Instruments: The Company will issue 10% senior secured convertible notes totaling $3.5 million (the "New Note"). The New Note is convertible at $0.15 per share.
- Existing Debt Amendment: A prior $3.0 million note (Original Note) was amended to extend maturity from July 1, 2016, to October 1, 2016.
- Equity Issuance (Immediate):
- 100,500,000 shares of common stock issued to Pharmsynthez.
- 11,000,000 shares of common stock issued to the Inventors (founders of Pharmsynthez) for patent assignment.
- Warrants Issued:
- New Warrant: Pharmsynthez receives warrants for up to 11,666,667 shares (exercise price: lesser of $0.20 or 120% of Capital Raise price).
- Management Warrants: Up to 5,000,000 shares for Pharmsynthez management (exercise price: $0.42).
- Future Capital Raise Obligation: The Company must secure at least $15 million in additional funding. Pharmsynthez is obligated to purchase $6.5 million of this equity.
Material Changes and Obligations
The filing outlines a material shift in the Company's capital structure and strategic direction:
- Ownership Structure: Pharmsynthez is positioned to own approximately 72% of the outstanding shares post-transaction (subject to a "Make Whole" provision if this threshold is not met).
- Corporate Action: The Company plans a reverse stock split of not less than 1:10 to facilitate listing on a U.S. national exchange.
- Listing Requirement: The Company must list its shares on a U.S. national exchange by March 31, 2016. Failure to do so triggers an additional loan obligation from Pharmsynthez up to the amount of the Pharmsynthez Purchase ($6.5 million).
- Compensation Conversion: Accrued unpaid compensation for the CEO and an affiliate of the CFO may be converted to common stock on pro rata terms with the New Note.
Guidance, Risks, and Contingencies
Contingencies: The transaction is subject to customary closing conditions, including stockholder approval of an amendment to the Articles of Incorporation (for the reverse split). The funding of the New Loan is tranche-based and contingent on written notice from the Company within specific windows (e.g., Dec 1-31, 2015; Feb 1-28, 2016).
Risks: The filing includes a Safe Harbor statement regarding forward-looking statements. Key risks include the Company's ability to successfully operate in a challenging economic environment, the success of the capital raise, and the ability to list on a U.S. exchange. The Company explicitly states it does not undertake an obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the status of the required $15 million capital raise and the $6.5 million commitment from Pharmsynthez.
- Confirm the approval of the 1:10 reverse stock split by stockholders.
- Monitor the tranche funding schedule for the $3.5 million New Loan to ensure liquidity.
- Review the full text of the Asset Purchase Agreement (Exhibit 10.1) for specific "Excluded Uses" and "Retained Territory" definitions regarding Virexxa.
- Check for the listing of Xenetic shares on a U.S. national exchange by the March 31, 2016 deadline.